<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321604</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002671</org_study_id>
    <nct_id>NCT03321604</nct_id>
  </id_info>
  <brief_title>Kidney Information Network for Disease Research and Education</brief_title>
  <acronym>KINDRED</acronym>
  <official_title>Kidney Information Network for Disease Research and Education (KINDRED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scott and White Hospital &amp; Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, Investigators will conduct a prospective cohort study of dialysis patients by&#xD;
      collecting research-quality information on patient characteristics, comorbid diseases and&#xD;
      laboratory markers used in routine practice, as well as novel biochemical markers and genetic&#xD;
      data. Investigators will utilize data from the cohort to test the independent relationship&#xD;
      between biochemical and genetic markers and Fabry disease and other rare diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KINDRED is a prospective observational cohort study that will enroll up to 5,000 dialysis&#xD;
      patients throughout the United States with and without known diagnosis of Fabry disease but&#xD;
      at risk for Fabry disease (e.g., unknown cause of renal disease, young male, initiating&#xD;
      dialysis without a kidney biopsy, etc).This tissue repository will allow for genetic&#xD;
      screening of a geographically diverse population, assist in identification of rare diseases&#xD;
      in ESRD, and collect research-quality information on risk factors and outcomes from an&#xD;
      ethnically heterogeneous population of dialysis patients. In this study, Investigators will&#xD;
      use a novel method of performing research in this population by leveraging the internet to&#xD;
      enhance and accelerate recruitment of potential subjects to participate in a genetic&#xD;
      screening/tissue repository protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">November 21, 2019</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Genetically determined Fabry disease prevalence amongst a heterogenous patient population with end-stage renal disease on dialysis in the US not previously known to have Fabry disease.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in patient characteristics of dialysis patients diagnosed with Fabry disease vs. dialysis patients who do not have Fabry disease.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in patient characteristics of individuals diagnosed with Fabry disease initiating dialysis after 2013 vs. patients with Fabry disease who started dialysis before 2003.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">338</enrollment>
  <condition>ESRD</condition>
  <condition>Fabry Disease</condition>
  <condition>Rare Diseases</condition>
  <condition>Kidney Diseases</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, Serum, DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults receiving dialysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 18 and 65 with ESRD undergoing dialysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney biopsy unlikely to be Fabry disease; those with a diagnosis that is clinically&#xD;
             or biochemically proven not to be Fabry disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://kindredresearch.mgh.harvard.edu</url>
    <description>KINDRED Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ravi Thadhani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Kidney</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Kindred</keyword>
  <keyword>Fabry</keyword>
  <keyword>Massachusetts General Hospital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

